Citadel Advisors’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-44,700
| Closed | -$16K | – | 8378 |
|
|
2016
Q3 | $16K | Buy |
44,700
+15,800
| +55% | +$5.66K | ﹤0.01% | 7110 |
|
|
2016
Q2 | $13K | Buy |
+28,900
| New | +$13K | ﹤0.01% | 6710 |
|
|
2016
Q1 | – | Sell |
-39,300
| Closed | -$58K | – | 9204 |
|
|
2015
Q4 | $58K | Sell |
39,300
-33,700
| -46% | -$49.7K | ﹤0.01% | 7194 |
|
|
2015
Q3 | $115K | Sell |
73,000
-23,300
| -24% | -$36.7K | ﹤0.01% | 6822 |
|
|
2015
Q2 | $164K | Buy |
96,300
+53,800
| +127% | +$91.6K | ﹤0.01% | 6565 |
|
|
2015
Q1 | $59K | Buy |
42,500
+9,300
| +28% | +$12.9K | ﹤0.01% | 7286 |
|
|
2014
Q4 | $50K | Sell |
33,200
-2,000
| -6% | -$3.01K | ﹤0.01% | 7209 |
|
|
2014
Q3 | $73K | Sell |
35,200
-31,500
| -47% | -$65.3K | ﹤0.01% | 6656 |
|
|
2014
Q2 | $204K | Sell |
66,700
-32,800
| -33% | -$100K | ﹤0.01% | 5547 |
|
|
2014
Q1 | $249K | Buy |
99,500
+30,800
| +45% | +$77.1K | ﹤0.01% | 5261 |
|
|
2013
Q4 | $341K | Buy |
68,700
+25,700
| +60% | +$128K | ﹤0.01% | 4475 |
|
|
2013
Q3 | $98K | Buy |
43,000
+25,800
| +150% | +$58.8K | ﹤0.01% | 5368 |
|
|
2013
Q2 | $38K | Buy |
+17,200
| New | +$38K | ﹤0.01% | 5803 |
|
Citadel Advisors's RXII Position: Q4 2016 in Review
Citadel Advisors sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 47,821 shares — an estimated $17K sold.
Citadel Advisors first reported a position in RXII in Q2 2013 and held it in 13 quarters. The position peaked at $284K in Q1 2014. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- Citadel Advisors reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- Citadel Advisors sold 47,821 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $17K.
- Citadel Advisors first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 13 quarters.
- Citadel Advisors's GALENA BIOPHARMA INC COM position peaked at $284K in Q1 2014.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on Citadel Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.